-
公开(公告)号：US12006502B2
公开(公告)日：2024-06-11
申请号：US18407815
申请日：2024-01-09
Inventor： HoWon J. Kim , In-San Kim , Jay S. Kim , Sun Hwa Kim , Ick Chan Kwon , Jong Won Lee , Yoo Soo Yang , Hong Yeol Yoon
IPC: C12N15/113 , A61P35/00 , C12Q1/68
CPC classification number: C12N15/1138 , A61P35/00 , C12N2310/11 , C12N2310/531
Abstract: Therapeutic compounds for red blood cell-mediated delivery of an active pharmaceutical ingredient to a target cell are described. The therapeutic compounds are configured to bind CD47 on the surface of a red blood cell and to be subsequently transferred to CD47 on the surface of the target cell, the therapeutic compound ultimately being internalized by the target cell via endocytosis. The target cell may be a fibrotic cell.
-
公开(公告)号：US11498946B2
公开(公告)日：2022-11-15
申请号：US17118767
申请日：2020-12-11
Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY
Inventor： Kwangmeyung Kim , Ju Hee Ryu , Hong Yeol Yoon , Man Kyu Shim , Suah Yang
Abstract: The present disclosure relates to a pharmaceutical composition for combination therapy for preventing or treating cancer, which contains a first pharmaceutical ingredient containing a drug conjugate wherein an anticancer agent is bound at one end of an amphiphilic peptide represented by SEQ ID NO 1 and a poloxamer; and a second pharmaceutical ingredient containing an anti-PD-L1 antibody; as active ingredients. The pharmaceutical composition significantly inhibits cancer growth in in-vivo experiments and exhibits an effect of significantly enhancing immunotherapeutic effect by activating immune cells in cancerous tissues.
In particular, the pharmaceutical composition for combination therapy according to the present disclosure has superior tumor accumulation efficiency and selectivity as compared to existing anticancer agents, and is very stable with little toxicity to normal tissues other than cancerous tissues.-
3.发明公开公开(公告)号：US20240325550A1
公开(公告)日：2024-10-03
申请号：US18618258
申请日：2024-03-27
Inventor： HoWon J. Kim , In-San Kim , Jay S. Kim , Sun Hwa Kim , Ick Chan Kwon , Jong Won Lee , Yoo Soo Yang , Hong Yeol Yoon
IPC: A61K47/64 , A61P35/00 , C12N15/113
CPC classification number: A61K47/64 , A61P35/00 , C12N15/113 , C12N2310/14 , C12N2310/141
Abstract: Therapeutic compounds for inhibiting and reducing the expression of cell surface proteins and methods for treating cancer, inflammation, and diabetes using the therapeutic compounds.
-
4.发明申请公开(公告)号：US20140140934A1
公开(公告)日：2014-05-22
申请号：US14074865
申请日：2013-11-08
Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY
Inventor： Kwang Meyung Kim , Ick Chan Kwon , Inchan Youn , Hyun Su Min , Hong Yeol Yoon , Jae Hyung Park
IPC: A61K49/22
CPC classification number: A61K49/223 , A61K49/0032 , A61K49/0069
Abstract: Disclosed is a liver tumor-targeting ultrasound contrast agent. The ultrasound contrast agent includes a gas-generating core and a hyaluronic acid shell. The ultrasound contrast agent can be specifically delivered to liver cells. This specific delivery enables easy differentiation between normal liver cells and liver tumor cells by ultrasound imaging. In addition, the ultrasound contrast agent is highly stable in aqueous condition and causes no cytotoxicity. Also disclosed is a method for preparing the ultrasound contrast agent.
Abstract translation: 公开了一种肝肿瘤靶向超声造影剂。 超声造影剂包括产气芯和透明质酸壳。 可以将超声造影剂特异性地递送至肝细胞。 这种特异性的传递使得通过超声成像能够容易地在正常肝细胞和肝肿瘤细胞之间进行分化。 此外，超声造影剂在水性条件下高度稳定，不产生细胞毒性。 还公开了一种制备超声造影剂的方法。
-
公开(公告)号：US12139713B2
公开(公告)日：2024-11-12
申请号：US18407780
申请日：2024-01-09
Inventor： HoWon J. Kim , In-San Kim , Jay S. Kim , Sun Hwa Kim , Ick Chan Kwon , Jong Won Lee , Yoo Soo Yang , Hong Yeol Yoon
IPC: C12N15/113 , A61P35/00 , C12Q1/68
Abstract: Therapeutic compounds for red blood cell-mediated delivery of an active pharmaceutical ingredient to a target cell are described. The therapeutic compounds are configured to bind CD47 on the surface of a red blood cell and to be subsequently transferred to CD47 on the surface of the target cell, the therapeutic compound ultimately being internalized by the target cell via endocytosis. The target cell may be a cancer cell.
-
Patent Agency Ranking
公开(公告)号：US11015197B2
公开(公告)日：2021-05-25
申请号：US16425849
申请日：2019-05-29
Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY
Inventor： Sun Hwa Kim , Ick Chan Kwon , Kwangmeyung Kim , Hong Yeol Yoon , Gi-Jung Kwak , Juho Park
IPC: C12N15/113 , A61P35/00
Abstract: The present invention relates to a novel anti-miRNA single-stranded nucleic acid maleimide derivative, which comprises an anti-miRNA single-stranded nucleic acid having a nucleic acid sequence complementary to a nucleic acid sequence of an miRNA. Further, the present invention provides an anti-miRNA single-stranded nucleic acid-serum albumin conjugate in which serum albumin is covalently bonded to the anti-miRNA single-stranded nucleic acid maleimide derivative via the maleimide group.
-
7.发明授权公开(公告)号：US09259493B2
公开(公告)日：2016-02-16
申请号：US14074865
申请日：2013-11-08
Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY
Inventor： Kwang Meyung Kim , Ick Chan Kwon , Inchan Youn , Hyun Su Min , Hong Yeol Yoon , Jae Hyung Park
CPC classification number: A61K49/223 , A61K49/0032 , A61K49/0069
Abstract: Disclosed is a liver tumor-targeting ultrasound contrast agent. The ultrasound contrast agent includes a gas-generating core and a hyaluronic acid shell. The ultrasound contrast agent can be specifically delivered to liver cells. This specific delivery enables easy differentiation between normal liver cells and liver tumor cells by ultrasound imaging. In addition, the ultrasound contrast agent is highly stable in aqueous condition and causes no cytotoxicity. Also disclosed is a method for preparing the ultrasound contrast agent.
Abstract translation: 公开了一种肝肿瘤靶向超声造影剂。 超声造影剂包括产气芯和透明质酸壳。 可以将超声造影剂特异性地递送至肝细胞。 这种特异性的传递使得通过超声成像容易地在正常肝细胞和肝肿瘤细胞之间分化。 此外，超声造影剂在水性条件下高度稳定，不产生细胞毒性。 还公开了一种制备超声造影剂的方法。
-
8.发明公开公开(公告)号：US20240360457A1
公开(公告)日：2024-10-31
申请号：US18765587
申请日：2024-07-08
Inventor： HoWon J. Kim , In-San Kim , Jay S. Kim , Sun Hwa Kim , Ick Chan Kwon , Jong Won Lee , Yoo Soo Yang , Hong Yeol Yoon
IPC: C12N15/113 , A61P35/00
CPC classification number: C12N15/1138 , A61P35/00 , C12N2310/11 , C12N2310/531
Abstract: Therapeutic compounds for red blood cell-mediated delivery of an active pharmaceutical ingredient to a cancer cell are described. The therapeutic compounds are configured to bind CD47 on the surface of a red blood cell and to be subsequently transferred to CD47 on the surface of the cancer cell, the therapeutic compound ultimately being internalized by the cancer cell via endocytosis.
-
9.发明公开公开(公告)号：US20240150771A1
公开(公告)日：2024-05-09
申请号：US18407815
申请日：2024-01-09
Inventor： HoWon J. Kim , In-San Kim , Jay S. Kim , Sun Hwa Kim , Ick Chan Kwon , Jong Won Lee , Yoo Soo Yang , Hong Yeol Yoon
IPC: C12N15/113 , A61P35/00
CPC classification number: C12N15/1138 , A61P35/00 , C12N2310/11 , C12N2310/531
Abstract: Therapeutic compounds for red blood cell-mediated delivery of an active pharmaceutical ingredient to a target cell are described. The therapeutic compounds are configured to bind CD47 on the surface of a red blood cell and to be subsequently transferred to CD47 on the surface of the target cell, the therapeutic compound ultimately being internalized by the target cell via endocytosis. The target cell may be a fibrotic cell.
-
10.发明公开公开(公告)号：US20240191237A1
公开(公告)日：2024-06-13
申请号：US18407780
申请日：2024-01-09
Inventor： HoWon J. Kim , In-San Kim , Jay S. Kim , Sun Hwa Kim , Ick Chan Kwon , Jong Won Lee , Yoo Soo Yang , Hong Yeol Yoon
IPC: C12N15/113 , A61P35/00
CPC classification number: C12N15/1138 , A61P35/00 , C12N2310/11 , C12N2310/531
Abstract: Therapeutic compounds for red blood cell-mediated delivery of an active pharmaceutical ingredient to a target cell are described. The therapeutic compounds are configured to bind CD47 on the surface of a red blood cell and to be subsequently transferred to CD47 on the surface of the target cell, the therapeutic compound ultimately being internalized by the target cell via endocytosis. The target cell may be a cancer cell.
-
-
-
-
-
-
-
-
-
Search Results
12
records
(took 0.017 seconds)
